• Intellia Therapeutics (NTLA) is down 4.2% today at $16.70 as traders engage in "sell the news" profit-taking after the company's recent Phase 3 success for its gene-editing therapy, lonvo-z.
  • The pressure is further amplified by recent insider selling by the CFO and ongoing concerns regarding commercialization hurdles and high short interest.
  • Broader market caution ahead of today's FOMC Minutes release and persistent geopolitical tensions are also contributing to the downward movement.